Nitresan (Nitrendipine)

Nitrendipine, the active ingredient in Nitresan, is a calcium channel blocker presented as an oral tablet for oral use. It is used to lower high blood pressure and to relieve chest pain caused by angina pectoris, primarily in adult patients. By selectively inhibiting calcium influx in vascular smooth muscle, it promotes vasodilation and reduces cardiac workload effectively.

GNH USA supplies Nitresan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance.

Nitrendipine is employed to manage cardiovascular conditions that involve elevated vascular resistance and myocardial oxygen demand.

Hypertension: Reduces both systolic and diastolic blood pressure by relaxing arterial smooth muscle, improving overall circulatory dynamics. Angina pectoris: Alleviates chest pain episodes by decreasing cardiac workload and enhancing coronary blood flow during exertion. Chronic stable angina: Provides long‑term symptom control for patients with persistent angina, helping to maintain exercise tolerance and quality of life.

Nitrendipine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache, often occurring during the first weeks of treatment. - Flushing: transient warmth and redness of the skin, usually brief and self‑limiting. - Peripheral edema: swelling of the ankles or lower legs due to fluid accumulation. - Dizziness: light‑headed sensation, especially upon standing or changing position. - Tachycardia: increased heart rate that may be noticed during activity or at rest.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause fainting or shock. - Hepatotoxicity: abnormal liver function tests or clinically significant liver injury. - Allergic reactions: rash, itching, or anaphylaxis occurring in rare cases. - Cardiac arrhythmias: irregular heart rhythms that may require medical evaluation.

When prescribing Nitrendipine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: Check baseline and periodic blood pressure to avoid excessive hypotension. - Cardiovascular assessment: Evaluate for existing heart failure or severe aortic stenosis before initiation. - Liver function: Perform liver enzyme tests periodically, especially in patients with hepatic impairment. - Pregnancy and lactation: Use only if potential benefit justifies risk, as safety data are limited. - Drug interactions: Review concomitant medications that may potentiate hypotensive effects. - Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and light.

Nitrendipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: Co‑administration may markedly increase nitrendipine plasma levels, raising risk of severe hypotension. - Grapefruit juice: Potentiates drug exposure through CYP3A4 inhibition, potentially leading to dangerous blood pressure drops.

Moderate Interactions (Monitor Closely): - Other antihypertensives: Combined use can cause additive blood pressure lowering; monitor for symptomatic hypotension. - Diuretics: May enhance electrolyte disturbances and orthostatic effects; adjust dosing as needed. - Beta‑blockers: Concurrent therapy may affect heart rate control; observe for bradycardia. - CYP3A4 inducers: May reduce nitrendipine effectiveness by increasing metabolism; consider alternative therapy.